Exact chases its dream with $1.7bn Thrive deal
Setting its sights on the screening setting, Exact aims to be a major liquid biopsy player.
Bayer looks for answers with $2bn Askbio acquisition
The German group hopes that boosting its presence in gene therapy will drive growth of its pharma business.
Biopharma buyouts still pricey
A global pandemic has done nothing to crimp M&A premiums, with acquirers forced to swallow ever higher price tags.
Gilead rescues biopharma’s takeout scene
A few multi-billion-dollar deals got done in the third quarter, but 2020’s acquisition scene still looks anaemic.
Bridgebio U-turn shows how money can be made twice over
The company becomes the third in two months to buy back a division it had spun out just a few years earlier.
Bristol bets big on Myokardia
The $13.1bn price suggests that Bristol could be banking on mavacamten’s potential outside rare diseases.
Few clues to flotation fever in past performance
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
